The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2024 | PET Imaging for PD-L1: advancing personalized treatment in esophagogastric cancer
Samuel Louis Cytryn, MD, from Memorial Sloan Kettering Cancer Center in New York, NY, discusses the challenges in translating findings from a pilot PET study (NCT04161781) into clinical practice for personalized treatment strategies and prognostic assessments in advanced esophagogastric cancer. The study utilized the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging, aiming to overcome limitations of single-site biopsies. Dr Cytryn highlights the heterogeneity of PD-L1 expression across different disease sites and institutions, emphasizing the need for comprehensive, non-invasive diagnostic tools. While the pilot study demonstrated safety, feasibility, and concordance with pathologic findings, larger cohorts are needed to validate these findings and explore potential applications in treatment selection and outcome prediction for patients receiving PD-1 blockade therapy. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
